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Background: An academic, community medicine partnership was established to build a phenotype-to-outcome
model targeting chronic pain. This model will be used to drive clinical decision support for pain medicine in the
community setting. The first step in this effort is an examination of the electronic health records (EHR) from clinics
that treat chronic pain. The biopsychosocial components provided by both patients and care providers must be of
sufficient scope to populate the spectrum of patient types, treatment modalities, and possible outcomes.
Methods: The patient health records from a large Midwest pain medicine practice (Michigan Pain Consultants, PC)
contains physician notes, administrative codes, and patient-reported outcomes (PRO) on over 30,000 patients during
the study period spanning 2010 to mid-2014. The PRO consists of a regularly administered Pain Health Assessment
(PHA), a biopsychosocial, demographic, and symptomology questionnaire containing 163 items, which is completed
approximately every six months with a compliance rate of over 95 %. The biopsychosocial items (74 items with Likert
scales of 0–10) were examined by exploratory factor analysis and descriptive statistics to determine the number
of independent constructs available for phenotypes and outcomes. Pain outcomes were examined both in the
aggregate and the mean of longitudinal changes in each patient.
Results: Exploratory factor analysis of the intake PHA revealed 15 orthogonal factors representing pain levels;
physical, social, and emotional functions; the effects of pain on these functions; vitality and health; and measures
of outcomes and satisfaction. Seven items were independent of the factors, offering unique information. As an
exemplar of outcomes from the follow-up PHAs, patients reported approximately 60 % relief in their pain. When
examined in the aggregate, patients showed both a decrease in pain levels and an increase in coping skills with
an increased number of visits. When examined individually, 80-85 % of patients presenting with the highest pain
levels reported improvement by approximately two points on an 11-point pain scale.
Conclusions: We conclude that the data available in a community practice can be a rich source of biopsychosocial
information relevant to the phenotypes of chronic pain. It is anticipated that phenotype linkages to best treatments
and outcomes can be constructed from this set of records.
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Overview
With the high prevalence of chronic pain in America, plus
the corresponding personal, social, and economic burdens
from pain [1–3], it is critical to have highly effective tools
and treatments available for pain medicine practitioners.
There is a growing consensus that evidence-based medicine
should be the guide for developing these tools and treat-
ments, but this is difficult to achieve due to the challenges
in obtaining sufficient data to deduce linkages between
treatments and outcomes [4]. For community-based practi-
tioners, evidence-based medicine must be effective in their
population and setting. Therefore, many advocate for prag-
matic approaches to meet this need [5] instead of the gold
standard, randomized controlled trials because they are ex-
pensive, complicated to execute [6], narrow in focus, and
not generally suitable for comparative effectiveness evalu-
ation in the community setting [7].
Pragmatic approaches to comparative effectiveness must
be built on the knowledge of the patients and their envir-
onment. Considering that the number of patient visits in
the US per year for all conditions is approximately 190
million [8], patient charts represent a vast, untapped re-
source that could be used to gather this knowledge [9].
Within this resource lies the collective experience of med-
ical practitioners and their patients. We conjecture that
extracting the content from this documentation can pro-
vide important background for the development of
evidence-based personalized treatment in pain medicine
and the opportunity for pragmatic comparative effective-
ness evaluations among existing treatments.
Extracting the collective experience of medical practi-
tioners requires comprehensive patient charts containing
detailed progress notes and patient reported outcomes
(PRO). In the field of chronic pain, this must encompass
the patient’s complete biopsychosocial phenotype, the
constellation of typical treatments, and the range of out-
comes. Pain medicine physicians have long grappled
with the issue of understanding how pain affects patients
and how objective measures can be created for the sub-
jective characteristics of chronic pain. Implementing
such measures has clinical, ethical, legal, and social ram-
ifications [10]. This is something the authors (FD, MG)
have struggled with throughout 30 years practice, ultim-
ately leading to the development of a patient self-
assessment and care management tool (PRISMTM). This
was designed to give each patient a consistent voice in
their medical record, reflecting the complexities and
multidimensional nature of pain and its effects on the
whole person. Supplementing this is the physician per-
spective recorded as text in detailed progress notes fol-
lowing an enhanced SOAP note format and rendered in
correspondence form. With these components available,
an opportunity now exists to utilize this community-based patient data to improve outcomes [11, 12] and
empirically justifying the appropriate use of pharmaceut-
ical and procedural interventions. This can be accom-
plished by converting the data to actionable information
through the use of data mining, natural language pro-
cessing, medical informatics, and decision support tools.
To utilize this data and move toward the goal of per-
sonalized therapy in pain management and eventually
to the goal of evidence-based pain medicine, Michigan
State University (MSU) has partnered with Michigan
Pain Consultants PC (MPC) and ProCare Systems, Inc.
to share data and expertise. ProCare developed a
physician-driven tool to capture comprehensive patient
data from community practice utilizing modern elec-
tronic techniques consistent with the drive to move
medicine into the ‘measured world’. This public-private
partnership between MSU, ProCare, and MPC was
established to evaluate and utilize this data repository
for research and development in the pervasive, costly,
and seemingly underfunded domain of medical pain
management. In its initial form, this repository will
offer the opportunity for pragmatic comparative effect-
iveness research, but with development it will allow
other research, such as clinical trials and development
of decision support models.
The immediate goal is to extract content from the
MPC reservoir of patient clinical data to identify
person-in-pain phenotypes and their associated inter-
vention outcomes. Two early steps toward this goal are
to determine if the ProCare repository of MPC data
captures a broad spectrum of patient phenotype char-
acteristics, and if suitable outcome measures can be
tracked during the course of patient care. Utilizing the
concepts of the biopsychosocial model of chronic pain
[13] as a guide, several patient characteristics are desir-
able to allow phenotype construction. These include:
physical, emotional, and social status of a patient; the
influence of these attributes on pain intensity; the ef-
fects of pain on these attributes; and patient outcomes
as declared by the patient and physician. Important
outcomes are progressive improvements in pain levels,
quality-of-life measures, and satisfaction with treat-
ment. Long term, the goal is to marry the phenotype of
the patient in pain with the genotype information now
mounting [14]. The combination of this information
will help guide patterns of treatment likely to result in
best outcomes for a particular set of genotype/pheno-
type expression. This will reduce the more subjective
aspects of pain medicine and will be a major step to-
wards personalized therapy.
The content of MPC’s clinical records comprises
practice management data, results from detailed patient
questionnaires, and detailed progress notes, all derived
from approximately 95,000 patient visits per year.
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note dictations [15] and early methods for extracting
content. Current work is underway to examine the in-
take (pre-treatment) PRISMTM Pain Health Assessment
(PHA) patient questionnaire to determine if select patient-
reported behaviors can be linked by potential cause-
and-effect relationships while controlling for a broad
spectrum of background patient characteristics (Reed
et al., manuscript in preparation). In addition, several
presentations on work derived from the clinical records
[16–20] have demonstrated several unique features of
the data and the commitment of the team to utilize it
for research.
In this report we examine some of the information con-
tent of the MPC clinical record within the context of the
biopsychosocial model, and also provide an initial examin-
ation of pain outcomes. In particular, we present an ex-
ploratory factor analysis of the PHA question set to
evaluate possible constructs represented by the items in the
questionnaire and we provide a preliminary mapping to
biological (medical), psychological, and social latent vari-
ables that would be part of a biopsychosocial phenotype
model for this population. This methodology is often used
to determine the factors contained within survey tools and
occasionally to assess construct validity (e.g., [21, 22]). We
conclude that the data available in this clinical practice is
likely suitable for the determination of many pain pheno-
types and outcomes. This offers the opportunity to build a
base for future research and enhanced care delivery.
Description of Electronic Health Record (EHR) and Pain
Health Assessment (PHA) Tool
Data content of electronic health record
The types and characteristics of the data stored in the
EHR at MPC are shown in Table 1. From this collection
of data the patient encounter trajectory of symptom, his-
tory, finding, diagnosis, treatment, and outcome can be
discerned. Once this information is extracted andTable 1 Estimated number of measurable variables available within
Category Variables
Demographic & Lifestyle 5 administrative 11 from PHA
Treatment codes 1 to 33 per patient
Drug codes 1 to 13 per patient
Prescription Drugs 10 major classes
Diagnosis codes 1 to 17 per patient
PHA Questionnaire 163 items representing multiple scales and s
Progress Notes
Canonical sections 8
Extractable variables Unknownanalyzed, the goal will be to deduce patient phenotypes
and the linkages to treatments and outcomes. All the
categories denoted in Table 1 are assumed to be import-
ant for success in model creation. This report will focus
on examining a portion of the PHA survey to estimate
its information content and potential usefulnessHistorical background: development and deployment of
the PHA
As part of MPC’s initial assessment, patients are asked
to complete an initial pain health assessment (iPHA).
MPC utilizes the PRISMTM Pain Health Assessment
(PHATM), developed by ProCare Systems, Inc., which
is a patient self-assessment instrument that provides
demographic, medical and social history, as well as
patient-reported outcomes (PRO). It contains core
outcome domains that evaluate the efficacy of treat-
ments, consistent with the recommendations of the
Initiative on Methods, Measurement, and Pain Assess-
ment in Clinical Trials (IMMPACT) [23, 24]. The
broad domains of the PHA are described in Table 2
with more details in Table 3. The full text of the 163
question set for the PHA are available upon request
from ProCare Systems for research purposes.
The development of the PHA was motivated by the
needs of community based physicians in the emerging
field of pain medicine to demonstrate the quality and
effectiveness of the care being provided. ProCare began
working with the American Academy of Pain Medicine
in the mid 1990’s as a beta test site for the Digimed
project. Although that system failed to produce the
sensitivity needed for the task, the project set the stage
for the evolution of other measurement systems.
In 2004, the TOPS [25] survey was mailed to patients
with a return mailing for their response. After six months
of trials, the completed return rate was roughly only 30 %.
In 2005, the TOPS tool was implemented in the MPCthe Electronic Health Records of MPC
Comment
Mean = 5.7
Mean = 3.4 Drugs used for procedures
90 % of all Rx in top 10 classes Mean = 4.6 Rx per
patient ~27 % of patients receive Rx
Mean = 3.7
ub-scales Patient-reported status and outcomes. Additional items
are included for narcotic risk, demographics and lifestyle.
Estimates from preliminary work would indicate at least
10 variables per section
Table 2 Categories, response types, and item counts for the
iPHA and the cPHA questionnaire
PHA Categories Response types items Comment
Demographic y/n item select 5 2 items in
iPHA only
Lifestyle & abuse history Item select 11 8 items in
iPHA only
Employment & disability y/null 20 In both iPHA
and cPHA
Syndromes & Diagnoses y/null 15 In both iPHA
and cPHA
Pain anatomic location y/null 17 iPHA only
Biopsychosocial (total) 11-pt Likert 95
iPHA only 11-pt Likert 7 Initial panel:
Pain interference
with daily life
cPHA only 11-pt Likert 21 Outcomes and
satisfaction
iPHA: intake PHA, filled out on or near the first visit
cPHA: continuing, follow-up PHA filled out at 3 mo, 6 months, and every 6
mo thereafter
Juckett et al. BMC Medical Informatics and Decision Making  (2015) 15:41 Page 4 of 14clinics. The original survey was difficult to administer with-
out interfering with patient flow in the clinic and addition-
ally, many scales were not sensitive enough to demonstrate
changes over time.
In 2007 substantial evolutionary changes to the sur-
vey and its administration were undertaken. The goal
was to develop a PRO tool that would not interfere
with clinic flow or add significantly to the cost of care.
The tool was composed of quality-of-life indicators, as
well as additional questions assessing functional im-
pairment, psychosocial health, and patient satisfaction.
Response scales were universally formatted to an 11-
point Likert scale to be sensitive enough to map incre-
mental changes. In 2009, technology allowed for a fully
functional web-based system that could be accessed
from any computer or tablet device. In 2011 an assess-
ment of narcotic risk was incorporated.
Currently, the PHA is self-administered by patients
using iPads provided in the clinic at check-in or through
the PRISMTM portal. Information from the PHA is in-
stantly analyzed and transferred to a Patient Summary
Page dashboard for the physician and care team to in-
form clinical decision making in real-time during the pa-
tient visit.
Current deployment characteristics
Two versions of the questionnaire are used in the prac-
tice: an initial assessment version (initial PHA or iPHA)
for new patients and a version for follow-up visits con-
taining repeated measures for most iPHA questions
plus the addition of specific outcome questions. (This
is referred to as the cumulative PHA or cPHA.). The
cPHA is also used for patients that did not complete aniPHA because their initial visit preceded its rollout.
The full questionnaire covers 39 categories with a total
of 163 items designed to assess pain characteristics, so-
cial and demographic characteristics, health behaviors,
habits, symptoms, narcotic risk, and self-reported syn-
dromes and symptoms. A breakdown of categories is
shown in Table 2. For the initial assessment, the ques-
tionnaire is limited to 34 categories and 142 items. For
the cPHA, five additional patient outcome and satisfac-
tion categories are activated, containing 21 items, while
three categories useful only for intake are deactivated,
yielding a total of 36 categories and 131 items. The
MPC practice typically follows patients on a long term
basis, with cPHA’s administered 3 monthsnths after
first treatment, 3 months later, and every 6 monthsnths
thereafter.Methods
Data
Michigan State University (MSU) through its Biomedical
Research Informatics Core (BRIC), a division of the MSU
Clinical and Translational Sciences Institute (CTSI) has en-
tered into a Business Associates agreement with Michigan
Pain Consultants (MPC) and ProCare Systems, Inc. MSU
BRIC houses de-identified copies of their Pain Health As-
sessment questionnaire, their de-identified practice man-
agement data, and their dictated clinical progress notes on
a secure workstation isolated from the internet, in compli-
ance with HIPAA regulations and IRB requirements.
The Michigan State University IRB has declared this
project to have a category 4 exempt status under 45
CFR 46.101(b)(4). Questionnaires from April 1, 2010 to
September, 2014 were used in this analysis because the
PHA question slate remained unchanged during this
span, except for the addition of the Opioid Risk Tool
[26] questions in 2011. The questionnaire data obtained
after this time period will be used in future work to
examine test administration consistency, test-retest re-
liability, and stability of phenotypes and outcomes.
During the study period, approximately 30,400 pa-
tients completed one or more PHA surveys. Of this
number, ~22,700 were new patients who completed the
iPHA. A total of ~61,000 cPHAs were completed, which
included patients who had completed the iPHA during
this span and patients who had completed previous ver-
sions of the iPHA or none at all due to their much lon-
ger history with the MPC clinics. Approximately 12,600
patients had completed both an iPHA and one or more
subsequent cPHAs during this span. The remainder of
patients with an iPHA had no cPHA primarily because
they either chose not to return or their return date was
outside the study period. Furthermore, there are occa-
sional workflow issues in the clinic that have hindered
Table 3 PHA question numbers and descriptive label of
question content
Questions PHA (Pain Health Assessment) descriptive labels
Q1 Ethnicity
Q2 Race
Q3 A – Q Symptoms
Q4 A – O Syndromes and Diagnoses
Q5 A – B Worst and Least Pain Today
Q6 A – G Pain interfering (past 24 h) with activity, mood,walking,
work, relationships, sleep, and enjoyment of life
Q7 Estimate of health
Q8 A – B Health limiting moderate activity, strenuous activity during
typical day
Q9 A – B Health (past 4 weeks) limiting accomplishments or work
Q10 A – B Emotional problems (past 4 weeks) limiting
accomplishments or work
Q11 Pain (past 4 weeks) interfering with work
Q12 A – C Feelings (past 4 weeks); calm and peaceful, lot of energy,
downhearted and depressed
Q13 Physical or emotional health (past 4 weeks) interfering
with social activities
Q14 Health compared to one year ago
Q15 A – C Worst pain, average pain, pain right now
Q16 A – P Activities of daily living
Q17 A Physical activity makes me hurt more
Q17 B – D Preconceptions; activity make me feel better, safe for me
to be active, I should do normal work
Q18 A - K Feelings (past 4 weeks). Pep, nervous, down in dumps,
worn out, happy, tired, anxious, worry, angry, depressed,
memory problems
Q19 A – F Pain getting in the way of; enjoying social activities, doing
social activities, family relationships, friend relationships,
pleasure with family, ability to plan
Q20 A – D Perception of control; life, handling problems, control of
pain, coping with stress
Q21 A – D Time devoted to; visiting friends, partaking in groups,
enjoying hobbies, activities outside the house
Q22 A – D Limitations (past 4 weeks), time on work or activities,
accomplishments, performance
Q23 Initial pain before treatment
Q24 Average daily pain at this point in treatment
Q25 Relief received from treatments and medications
Q26 A - G Improvement in; activity, mood, walking, work,
relationships, sleep, enjoyment of life
Q27 A - K Rating of clinical experience; time, courtesy, confidence,
quality, administration, confidence of recommendations
Q28 A - M Questions regarding employment status and disability
Q29 A - G Specific questions regarding disability support
Q30 Marital status
Q31 Persons in household
Q32 Education
Q33 Smoking habits
Table 3 PHA question numbers and descriptive label of
question content (Continued)
Q34 Alcohol use
Q35 History of substance abuse
Q36 Family history of substance abuse
Q37 Preadolescent sexual abuse
Q38 Who completed PHA
Q39 How was PHA completed
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them from complying. Those patients with both iPHA
and cPHA during this period had completed approxi-




Preliminary exploratory factor analysis (EFA) of the PHA
battery of questions (as implemented by the principle factor
methodology in Stata™ v12) examined both the iPHA and
cPHA repository. Cronbach’s alpha [27] and inter-item cor-
relations were also calculated to help identify questions
with similar response characteristics. After orthogonal rota-
tion, factor assignments were made by examining eigen-
values, factor loading values, and alpha values for those
observed variables with high inter-variable correlations.
These assignments were then evaluated for their internal
consistency and applicability as constructs within a biopsy-
chosocial model.
Outcome analysis
To provide preliminary evidence for the utility of the
PHA in pain outcomes, we focused on a small subset of
questions. The PHA questions of interest for this ana-
lysis are:
Ques.1. Overall, how much relief have you received from
pain treatments and medications? Please fill in the
percentage that shows how much relief you have
received. (0–10) 0 % - 100 %;
Ques.2. “On a scale of 0–10, please rate your average
pain in the past 4 weeks”;
Ques.3. “Fill in the number that best describes your
average daily pain at this point in treatment at the pain
management center. Please rate (0–10) No pain – worst
pain”;
Ques.4. “On a scale of 0 to 10… Your control over your
pain. (0–10) Complete – None”
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questions do not appear in this order or in these posi-
tions in the PHA, but have been enumerated here for
easy reference.) In each of these questions, the responses
are on an 11-point Likert scale ranging from 0–10. For
question Ques.1, this scale was presented to patients as
percent relief (0 – 100 %).
Results
Exploratory factor analysis
The PHA was assembled to evaluate multiple patient di-
mensions by deploying several question items that poten-
tially consolidate into factors and therefore may be
combined into scale scores useful as representations of con-
structs in models and decision support engines. While the
items in the PHA were inspired by existing pain question-
naires, the reliability, validity, and construct mapping of
item sets deployed in the PHA were not determined a
priori in pilot studies. Rather, the decision was made by
ProCare to collect large quantities of responses within the
environment of a community-based. multi-site medical
practice to allow the data to drive the organization of con-
structs from identifiable factors. Once in place, reliability
and validity estimates can be made. Therefore, we begin
with an unbiased examination of these items using explora-
tory factor analysis to identify groups of items that have
high inter-item correlation, strong factor loadings, and high
Cronbach alpha values. The goal is to determine which
questions can be combined into relatively homogenous
scales and which questions provide unique information and
should stand alone. In contrast to efforts to design question
batteries that can be combined into scales representing
conceptual constructs (e.g., [22]), this work starts with a
broad battery of questions relevant to chronic pain patients
and seeks to identify subsets of questions that may repre-
sent constructs valuable in modeling phenotypes of chronic
pain patients.
As shown in Table 2, there are multiple categories in the
PHA that will be important contributors to a phenotype
model. As shown in Table 1, the PHA itself is only a por-
tion of the total data repository of the EHR that will be crit-
ical to building a comprehensive model with predictive
power. Within the iPHA, the biopsychosocial categories are
composed of 74 questions that are asked before treatment.
Examining the suitability of factor analysis for this set using
the KMO test yielded a value of 0.96, indicating that 96 %
of the variability in the data may be caused by underlying
factors. Therefore, EFA was performed and yielded eigen-
values with a pattern in the scree plot that suggested as
many as 30 factors may be significant using the threshold
criterion of Cattell (1966) [28]. This number was deemed
overly large and a more conservative approach was taken.
Using the random matrix criterion of Horn (1965) [29], a
full set of random answers (ranging over 0 – 11) wereconstructed for all 74 variables and all patients. Factor ana-
lysis of this data set yielded eigenvalues plotted in Fig. 1, to-
gether with the eigenvalues for the iPHA factor analysis. If
we assume that all factors worth considering should lie
above the highest eigenvalue of the random set, then 14 or
15 factors are likely to be important (see inset of Fig. 1).
Choosing 15 factors for the analysis yielded 15 identifi-
able clusters with two or more questions per factor
(Table 4). Seven of the 74 questions did not fall strongly
into any factors (loadings < 0.4) and were uncorrelated
with each other, suggesting that they offer unique, inde-
pendent information. These are shown in Table 5.
In Table 4, a summary of the factor metrics and infor-
mal descriptions are given for iPHA exploratory factor
analysis. In the analysis of the iPHA, the subject to item
ratio is approximately 300:1. This is the very high end of
typical studies and well beyond the recommended 20:1
ratio [30], therefore the results should be robust. Some
of the findings among the factors are that there was a
separation between performing and enjoying activities;
coping was separate from other mental health character-
istics; and, coarse motor activities were separate from
fine motor activities. Work and hobbies separated from
each other and pain and pain effects separated. The high
mean loadings and Cronbach alphas support this pattern
of item consolidation. As an informal examination of
test-retest validity, EFA of the cPHA questions that are
in common with the iPHA questions yielded almost
identical factoring with only two questions changing fac-
tor assignments (not shown). This was due to relatively
weak loading values (between 0.4 and 0.5) in each of
these two cases, in both the iPHA and cPHA analyses.
The communality values in Table 4 are indicators of
the average fraction of the variance that the factors con-
tribute to the question responses. It is clear from these
values that while the common factor loadings account
for substantial variance, unexplained variance remains.
This is attributable to unique factors – components spe-
cific to each question plus experimental error. These
unique factors are by definition uncorrelated with each
other and their non-error components contribute to the
information content of each question. This information
may be important to any model of patient phenotypes
and must be included in model construction. Tech-
niques such as structural equation modeling (SEM) ac-
count for this unique information and will be employed
in future work during phenotype model design and
testing.
To examine the degree of independence among the 15
identified factors from the iPHA analysis (Table 3),
scales were created for each factor by computing the
mean of each result variable within each factor for each
patient, creating 15 new variables per patient. A fre-































Fig. 1 Exploratory factor analysis Scree plot. Scree plot for the exploratory factor analysis of the iPHA data set and for a data set of the same dimensions
composed of random answers
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Fig. 2. Most of these correlations (~92 %) are between -0.5
and 0.5, indicating weak to moderate correlations and
high independence among factors, but there are a few
values (7.6 %) above 0.5 indicating that future modelingTable 4 Results of exploratory factor analysis on ~ 22,700 iPHA ques
Factor Informal factor description # of items Mean loading Mean a
1 Pain on ADL - torso 9 0.726 0.945
2 Pain affecting work 8 0.600 0.943
3 Mental health 8 0.565 0.901
4 Pain on ADL – fine motor 6 0.644 0.894
5 Pain intensity 6 0.670 0.865
6 Social interactions 4 0.554 0.848
7 Coping ability 3 0.692 0.900
8 Effects of pain – past 24 h 5 0.532 0.900
9 Social activities 4 0.534 0.811
10 Mental state affecting work 2 0.791 0.964
11 Pain affecting hobbies 2 0.452 0.930
12 Vitality - pep 3 0.751 0.738
13 Pain affecting jaw 2 0.666 0.864
14 Vitality - tiredness 2 0.632 0.825
15 Pain-work attitude 3 0.446 0.690may need to include correlation terms between a few
factors. On the other hand, there are no notably high
correlations between factor variables suggesting that
the identified factors can be utilized as initial estimates
for measures of patient characteristics.tionnaire responses
lpha Mean communality Variables in factor
0.726 Q6-C, Q8-B, Q16-I, Q16-J, Q16-K, Q16-L,
Q16-M, Q16-N, Q16-O
0.758 Q8-A, Q9-A, Q9-B, Q11, Q22-A, Q22-B,
Q22-C, Q22-D
0.563 Q12-C, Q18-B, Q18-days, Q18-G, Q18-H,
Q18-I, Q18-J, Q18-K
0.618 Q16-A, Q16-B, Q16-C, Q16-D, Q16-E, Q16-H
0.554 Q5-A, Q5-B, Q6-F, Q15-A, Q15-B, Q15-C
0.621 Q19-C, Q19-D, Q19-E, Q19-F
0.745 Q20-A, Q20-B, Q20-D
0.686 Q6-A, Q6-B, Q6-D, Q6-E, Q6-G
0.530 Q21-A, Q21-B, Q21-C, Q21-D
0.878 Q10-A, Q10-B
0.816 Q19-A, Q19-B
0.485 Q12-A, Q12-B, Q18-A
0.672 Q16-F, Q16-G
0.520 Q18-D, Q18-F
0.463 Q17-B, Q17-C, Q17-D
Table 5 Questions with no significant loadings on any of the
15 factors
Question Paraphrased question content
Q7 In general would you say your health is: (0–10),
(excellent – poor)
Q13 In past 4 weeks how much has health or emotions
limited social activity (0–10), (none of time – all of time)
Q14 Compared to one year ago, how do you rate your
health (0–10), (much better – much worse)
Q16-P Does your health now limit you in sitting: (0–10), (not
at all – a lot)
Q17-A Physical activity makes me hurt more (0–10),
(completely agree – completely disagree)
Q18-E How are you feeling in past 4 weeks: Have you been a
happy person? (0–10), (none of time – all of time)
Q20-C Your control over your pain (0–10), (complete – none)
Juckett et al. BMC Medical Informatics and Decision Making  (2015) 15:41 Page 8 of 14In the follow-up questionnaire, the 21 questions unique
to the cPHA (Q23 – Q27) formed two factors plus three
questions that did not have strong loadings. Two of those
outcome questions (Q24, Q25) are analyzed below
(Ques.1 and Ques.3). With regard to the two identified
factors, one is composed of 11 questions related to patient
satisfaction with the clinical experience (Q27). The other
contains seven questions regarding biopsychosocial health
improvements after treatments (Q26). These question bat-
teries have alpha values of 0.96 and 0.94, respectively, and
in a cPHA factor analysis they consolidate into factors
with mean loadings of 0.85 and 0.78, respectively. In order
to fully examine the factors for the cPHA, the cases must
be sorted into groups denoted by which cPHA in a pa-

















Fig. 2 Frequency distribution of the correlation matrix. Frequency distribut
factors shown in Table 3. All possible combinations of the scales generatehaving only one cPHA on file (20,300) to ten on file (42).
Full factor analyses for these groups are outside the scope
of this report.
Outcomes analysis
In the previous section, a portion of the PHA was shown to
contain identifiable structure that would help populate
components of a person-in-pain phenotype model. To be a
comprehensive dataset, it must also contain viable out-
comes information to allow the full phenotype-treatment-
outcome model to be constructed. A sample of outcome
measures is explored in this section.
Responses to question Ques.1 (see Methods section)
strongly indicated that patients experienced benefit from
the care received. This is shown in Fig. 3 as the frequency
distribution for responses to this question. This effect is
corroborated by responses to questions Ques.2, Ques.3,
and Ques.4. In Fig. 4a it is shown that the fraction of pa-
tients with lower overall pain levels increased with time as
documented in their subsequent cPHA responses. In
Fig. 4b, a similar effect is seen for the patient’s ability to
cope with pain. The trend was demonstrated by consolidat-
ing the 11-point pain scale into three broad ranges (low
pain: 0 to 3; medium pain: 4 to 6; and high pain: 7–10) for
Ques.2 and Ques.3, and (high coping: 0 to 3; medium cop-
ing: 4 to 6; and low coping: 7–10) for Ques.4. With increas-
ing visits, there is a consistent reduction in the percentage
of with high pain levels and low coping levels. These are ag-
gregate results and the numbers of patients with 1, 4 and 7
cPHAs on file are shown at the top of the chart and labeled
as “Actual #”. Due to the continual influx of new patients
over the four years of the stable version of the PHA, not all0 0.2 0.4 0.6 0.8 1
or Correlation























Fig. 3 Responses to Question 1. Responses to Ques.1 from 61,161 patients who have completed the cPHA
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reached their 4th or 7th cPHA. The maximal possible
numbers who could have reached their 4th or 7th
cPHA are shown above the charts as “Possible #”. The
approximate timings of the PHAs are shown along the
bottom of the figure. These descriptive results are not
meant to be conclusive but are presented only to dem-
onstrate the breadth of the data and its capacity to sup-
port the goal of phenotype construction and/or
hypothesis testing.
While aggregate results are enlightening, longitudinal
intra-patient responses offer a more robust examination of
treatment responses. Therefore, within-patient pain out-
comes were examined in the patient population that had
both iPHA and cPHA responses on file from the April
2010 to September 2014 time period. This was approxi-
mately 12,600 patients. From this group two subpopula-
tions were identified: one that had initial responses to
Ques.2 within the range 1–9 (approximately 11,900 pa-
tients); and one that had initial responses only in the range
7–9 (approximately 4600 patients). Question #2 requests a
patient’s pain level within the previous four weeks. We used
the responses to this question in the iPHA as an indicator
of starting pain levels. Outcomes from treatment were ex-
amined by calculating the numeric change in responses to
Ques.2 in the subsequent visits when the cPHA was filled
out, and by examining the responses to Ques.3, which is
specifically worded as an outcome question and exists only
in the cPHA.
To obtain an appreciation for the range of responses ra-
ther than simple averages, the distributions of patient out-
comes were calculated. The distributions of the changes in
patient pain levels with time are shown in Fig. 5. For displaysimplicity, values are plotted as if continuous. In panel A,
the distribution of the differences between initial responses
to Ques.2 and subsequent responses to Ques.2 are shown
for all patients with starting pain within the range of 1–9.
The pain difference was calculated by averaging all the
cPHA responses for a particular patient before subtracting
the initial pain level. This approach is repeated in panels B,
C, and D of Fig. 5. In panel b, the outcome question Ques.3
of the cPHA is used as a comparison to the initial pain re-
sponses of Ques.2 in the iPHA. As in panel A, these
are calculated for patients with initial pain levels in the
range of 1–9. Panels C and D repeat the approach used
in panels A and B, except the calculations are limited
to high-pain patients; those with initial pain levels in
the range of 7-9. Patients with initial pain levels of zero
and ten are excluded because scale ceiling and floor
values can only allow changes in one direction and this
has the potential to skew the results. Excluding the pa-
tients with the extreme values of 0 and 10 represented
only approximately 3 % patients with both iPHA and
cPHA surveys in their clinical record.
The distributions within Fig. 5 are all fairly smooth, uni-
modal, and significantly shifted from zero (p < 0.001), indi-
cating substantial improvements in pain levels. Metrics for
these distributions are given in Table 6. While the best out-
comes are seen for those patients with the highest starting
pain, a high percentage of patients experienced a reduction
in pain. This is shown as the percentage of “Patients Im-
proving” in Table 6. The distributions of Fig. 5 also reveal
that a substantial number of patients reported reductions
in pain levels of 3, 4, 5, and even 6 pain units. It should be
noted that the larger effects in the high pain patients must
































Possible #       22,692                      20,900                     11,500                      6,300
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Possible #       22,692                      20,900                     11,500                      6,300
Actual #        22,692                      20,282                       6,415                      2,105 B
Fig. 4 Responses to Questions 2–4. Responses to questions Ques.2, Ques.3, and Ques.4 for intake and continuing PHA patient surveys. a The 11-point
pain scale was consolidated into three ranges (low pain: 0 to 3; medium pain: 4 to 6; and high pain: 7–10). Ques.2 was used for the intake PHA, while
the outcome Ques.3 was used for all the cPHA. The number of patients that have completed the respective surveys are shown at the top of the figure
as “Actual #”. The possible number who could have completed 1 or more cPHAs is shown at the top of the figure as “Possible #”. The nominal
times between the iPHA and subsequent cPHAs are shown below each column. b The 11-point coping scale for Ques.4 was consolidated into three
ranges (high coping: 0 to 3; medium coping: 4 to 6; and low coping: 7–10). The number of patients that have completed the respective surveys are
shown at the top of the figure as “Actual #”. The possible number who could have completed one or more cPHAs is shown at the top of the figure as
“Possible #”. The nominal times between the iPHA and subsequent cPHAs are shown below each column
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Likert scale unrelated to treatment. A formal evaluation
of the size of this effect is outside the scope of this
current presentation.Discussion
Health records from a community-based pain medicine
practice have been described and a preliminary evalu-
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Fig. 5 Intra-patient changes in responses to questions of pain levels. Intra-patient changes in responses to questions of pain levels. a Patients with
starting pain levels (Ques.2) in the range 1–9 are evaluated for mean pain level change as determined by answers to Ques.2 in the cPHA surveys.
b Patients with starting pain levels (Ques.2) in the range 1–9 are evaluated for mean pain level change as determined by answers to Ques.3 in
the cPHA surveys. c Patients with starting pain levels (Ques.2) in the range 7–9 are evaluated for mean pain level change as determined by answers to
Ques.2 in the cPHA surveys. d Patients with starting pain levels (Ques.2) in the range 7–9 are evaluated for mean pain level change as determined by
answers to Ques.3 in the cPHA surveys. Characteristics of the distributions are given in Table 4
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September, 2014. The patient population is con-
strained by the demographics, socio-economic profile,
and local referral patterns of the region. In this case,
the 7 community clinics of Michigan Pain Consultants
represent an upper Midwest USA region serving 6
counties in West Michigan containing medium-sizedTable 6 Characteristics for distributions in Fig. 5




Panel A −1.10 1.89 0.017 71.98 % 11,927
Panel B −1.21 2.01 0.018 72.58 % 11,927
Starting Pain 7-9
Panel C −1.85 1.72 0.030 88.17 % 4598
Panel D −2.10 1.95 0.029 85.87 % 4598
aValues are in units of the 11-point pain scale. Negative values indicate a shift
to less pain
bZ-scores calculated from the Means and Standard Errors indicate that these
distributions are significantly different from identical distributions centered at
zero (p-values < <0.001)
c“Patients Improving” is calculated from a normal distribution using the means
and standard deviations of the distributions of Fig. 4. The area to left of zero is
taken as representing patients improving, provided as a percentage, under the
assumption of a continuous scaleurban, suburban and rural environments. The patients
seen by this practice are those with commercial or
government medical insurance or have the means for
private pay. As such, the findings, while broad, cannot
be generalized to large urban centers or to the poor
without further work to show that the resulting phe-
notypes cross these boundaries.
This work is part of a larger study designed to con-
struct a phenotype – treatment – outcome model for
pain medicine. Our working hypothesis is that knowing
phenotype profiles for pain patients will help predict ap-
propriate treatments associated with better outcomes
and that this type of data can be extracted from commu-
nity clinical practice, where most chronic pain is treated.
A university-community partnership was established to
provide a foundation for this study. The first goal was to
determine if the pain clinic medical record database
(EHR) contained sufficient information to construct a
model. The MPC EHR is composed of practice manage-
ment data, patient questionnaires, and physician pro-
gress notes with a longitudinal component available for
many patients.
In this study, we show that the biopsychosocial com-
ponent of the patient questionnaire contains identifiable
factors that will allow combining question items into
Juckett et al. BMC Medical Informatics and Decision Making  (2015) 15:41 Page 12 of 14measures of interest for a phenotype model. It should be
noted that no inferential statistical methods are available
for exploratory factor analysis, thus there is a subjective
element to the choice of the number of eigenvalues and
acceptance/rejection criteria for correlations, loadings,
and Cronbach alpha values. Nevertheless, from explora-
tory factor analysis, preliminary models can be con-
structed and confirmatory factor analysis can provide
the statistical tests to evaluate these models. We will use
the data acquired after September, 2014 for this type of
work.
It will also be important to identify the factors (latent
variables) in the practice management data, the progress
notes, and in the remainder of the PHA data. Larger
models can then be constructed, initially tested with
CFA and then comprehensively tested with structural
equation modeling (SEM) [31]. It is desirable that the
larger models encompass the full patient encounter axis
of symptom, history, finding, diagnosis, treatment, and
outcome. Once the latent factors are identified, the next
step toward phenotype definitions will be determining
the latent classes that the patients cluster into. Whereas
factor analysis groups items into common factors, latent
cluster (class) analysis identifies groups of patients hav-
ing similar patterns of responses to the items (or similar
patterns of factor scores) using one of several available
methods (e.g., [32, 33]). These clusters will be our initial
phenotypes. Preliminary examinations of patient re-
sponses to a few subsets of factors indicate that strongly
orthogonal clusters of patients exist in the iPHA set,
using the k-means clustering algorithm. A full analysis
of clustering will be the subject of a follow-up paper.
After the phenotype models are derived and validated.
they can be used to generate hypotheses for future re-
search, which can provide the basis for evidence-based
medicine and decision support tools.
The preliminary examination of pain outcomes showed
that pain indicators can be followed with time. In the ana-
lysis of the patient outcomes it is useful to note that the
mean improvement of pain levels across repeated visits was
approximately one to two units on an eleven-point scale.
This degree of improvement was consistent with previous
validation studies on small patient numbers utilizing other
pain scale tools [34–36]. This suggests that both the PHA
responses and the population being treated are typical of
the chronic pain environment. Furthermore, it was shown
that patient improvement increased with visit number and
patients with the highest initial pain levels reported the
greatest improvement. This indicates that the patients are
improving and therefore the practice and its data reservoir
should meet the needs of our long-term study goals. In
addition to the specific outcome questions examined in this
study, other outcome metrics can be derived from the lon-
gitudinal trajectory of patient responses to all questions inthe cPHA. This can supply supportive evidence for changes
in well-being and quality of life that are part of the total pic-
ture of pain management.
This approach is important for the field of pain medi-
cine and for the patients receiving therapy. The use of
systems like the PRISMTM care management clinical
outcomes tool helps to assess the efficacy of interven-
tional treatments and helps guide physicians in the use
of opiates and other medications¹. There are many con-
cerns with opioid therapies and how they are monitored
in chronic pain patients [37]. For many patients they are
an important part of managing their pain . For others,
there are abuse problems. Similarly, interventional ther-
apies help many patients but not all [38]. Documenting
the biopsychosocial, patient and physician perspectives
enhances decision-making which can lead to more per-
sonalized care that can address these differences. Pro-
Care has already developed tools that have been utilized
to determine the best use of opioids and to garner out-
comes from procedures applied to populations of pa-
tients. This information has been fed back to the
physicians resulting in a reduction of imaging and nar-
cotic usage while maintaining patient satisfaction, thus
leading to increased value and safety. This has helped es-
tablish better working relationships with payers and is a
potent tool for patient advocacy.
Finally, it must also be noted that many patients stop
returning after varying numbers of visits. This leads to
many patients with only the iPHA on file and/or only a
few cPHAs on file. The reasons for patients not return-
ing are probably many. After an initially scheduled
follow-up visit, a patient may not return because their
pain is adequately under control, or they did not receive
any relief, or they left the area, changed insurance plans
or have other financial barriers, or they are deceased. It
is important that we determine the size and characteris-
tics of these sub-populations to make meaningful longi-
tudinal predictions of outcomes. These patient decisions
will also need to be part of the chronic pain phenotype
profile. This will be one focus of future work based on
sampling surveys.Conclusions
In conclusion, early results are presented that lay the
groundwork for extracting patient and physician perspec-
tives in a community pain medicine specialist practice. We
have demonstrated that multiple biopsychosocial variables
and pain level outcomes are being captured by the various
tools used by the practice.. We believe that these data can
be used to begin building phenotypes for persons in
chronic pain and the linkages to treatments and outcomes
that, in turn, can be used to facilitate evidence-based, per-
sonalized treatment of pain in community settings.
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1ProCare Systems has been in substantive discussions
with the State of Michigan Department of Community
Health to utilize the PRISM System and PHA to form
the foundation of a care management system to assist
physicians prescribing opioids for chronic pain patients.
This system will also be utilized to help better manage
the use of Suboxone therapy for treatment of addiction
disorders.
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